Literature DB >> 12858060

The enigma of multiple sclerosis: inflammation and neurodegeneration cause heterogeneous dysfunction and damage.

Trevor Owens1.   

Abstract

PURPOSE OF REVIEW: The demyelinating disease multiple sclerosis has an autoimmune inflammatory component, which has dominated the description of multiple sclerosis. A degenerative component to multiple sclerosis was always apparent, but was underappreciated until recently. Recent work has brought axonal pathology and brain atrophy into new focus. The purpose of this review is to highlight the relative roles played by the inflammatory and degenerative processes in multiple sclerosis pathology. RECENT
FINDINGS: In the past year reports have been published to show that early disability and disease progression correlate with axonal damage, and that brain atrophy resulting from axonal loss is a feature of early multiple sclerosis, and is not restricted to the secondary progressive forms of the disease. Inflammatory mediators (CD8 T cells and antibodies) are implicated in axonal damage, and treatment with steroids or anti-inflammatory therapies reduce brain atrophy, pointing to the involvement of the inflammatory response in the initiation of degeneration. Reduced regenerative capability also contributes to degeneration, and inflammatory responses are shown to inhibit the growth and migration of precursor cells for oligodendrocytes.
SUMMARY: Oligodendrocyte precursors are abundant in multiple sclerosis lesions, but fail to remyelinate. Oligodendrocyte growth and regeneration are probably compromised by the action of growth inhibitory signals and lack of growth stimuli. Inflammatory cells and mediators induce axonal loss as well as demyelination. The degenerative response is therefore an integral and early component of multiple sclerosis.

Entities:  

Mesh:

Year:  2003        PMID: 12858060     DOI: 10.1097/01.wco.0000073925.19076.f2

Source DB:  PubMed          Journal:  Curr Opin Neurol        ISSN: 1350-7540            Impact factor:   5.710


  30 in total

Review 1.  What do we know about the mechanism of action of disease-modifying treatments in MS?

Authors:  Hans-Peter Hartung; Amit Bar-Or; Yannis Zoukos
Journal:  J Neurol       Date:  2004-09       Impact factor: 4.849

Review 2.  Role of microglia in multiple sclerosis.

Authors:  Xinqing Deng; Subramaniam Sriram
Journal:  Curr Neurol Neurosci Rep       Date:  2005-05       Impact factor: 5.081

3.  Therapeutic effect of vasoactive intestinal peptide on experimental autoimmune encephalomyelitis: down-regulation of inflammatory and autoimmune responses.

Authors:  Elena Gonzalez-Rey; Amelia Fernandez-Martin; Alejo Chorny; Javier Martin; David Pozo; Doina Ganea; Mario Delgado
Journal:  Am J Pathol       Date:  2006-04       Impact factor: 4.307

4.  Cognitive deficit associated with cholinergic and nerve growth factor down-regulation in experimental allergic encephalomyelitis in rats.

Authors:  Giulia D'Intino; Michela Paradisi; Mercedes Fernandez; Alessandro Giuliani; Luigi Aloe; Luciana Giardino; Laura Calzà
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-14       Impact factor: 11.205

5.  Gamma interferon signaling in macrophage lineage cells regulates central nervous system inflammation and chemokine production.

Authors:  Adora A Lin; Pulak K Tripathi; Allyson Sholl; Michael B Jordan; David A Hildeman
Journal:  J Virol       Date:  2009-06-10       Impact factor: 5.103

6.  Continued administration of ciliary neurotrophic factor protects mice from inflammatory pathology in experimental autoimmune encephalomyelitis.

Authors:  Tanja Kuhlmann; Leah Remington; Isabelle Cognet; Lyne Bourbonniere; Simone Zehntner; Florence Guilhot; Alexandra Herman; Angélique Guay-Giroux; Jack P Antel; Trevor Owens; Jean-François Gauchat
Journal:  Am J Pathol       Date:  2006-08       Impact factor: 4.307

7.  Adrenomedullin protects from experimental autoimmune encephalomyelitis at multiple levels.

Authors:  Marta Pedreño; Maria Morell; Gema Robledo; Luciana Souza-Moreira; Irene Forte-Lago; Marta Caro; Francisco O'Valle; Doina Ganea; Elena Gonzalez-Rey
Journal:  Brain Behav Immun       Date:  2013-12-07       Impact factor: 7.217

Review 8.  Exercise and multiple sclerosis.

Authors:  Lesley J White; Rudolph H Dressendorfer
Journal:  Sports Med       Date:  2004       Impact factor: 11.136

9.  Leptin enhances the release of cytokines by peripheral blood mononuclear cells from relapsing multiple sclerosis patients.

Authors:  Giovanni Frisullo; Francesco Angelucci; Massimiliano Mirabella; Marcella Caggiula; Katia Patanella; Viviana Nociti; Pietro Attilio Tonali; Anna Paola Batocchi
Journal:  J Clin Immunol       Date:  2004-05       Impact factor: 8.317

Review 10.  The complement cascade: Yin-Yang in neuroinflammation--neuro-protection and -degeneration.

Authors:  Jessy John Alexander; Aileen Judith Anderson; Scott Robert Barnum; Beth Stevens; Andrea Joan Tenner
Journal:  J Neurochem       Date:  2008-10-24       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.